

ORIGINAL ARTICLE

Comparison study of a long-pulse pulsed dye laser and a long-pulse pulsed alexandrite laser in the treatment of port wine stains

LI LI¹, TARO KONO¹, WILLIAM FREDERICK GROFF², HENRY H. CHAN³,
YOSHIHIKO KITAZAWA¹ & MOTOHIRO NOZAKI¹

¹Department of Plastic and Reconstructive Surgery, Tokyo Women's Medical University, Tokyo, Japan, ²Division of Cosmetic Dermatology, La Jolla Cosmetic Surgery Centre, La Jolla, California, USA, and ³Division of Dermatology, Department of Medicine, University of Hong Kong, Department of Medicine / Therapeutic and Pediatric, Chinese University of Hong Kong, Hong Kong, China

Abstract

Background: Port wine stains (PWSs) are commonly treated by the pulsed dye laser. Recently, a long-pulse pulsed alexandrite laser was used to treat bulky vascular malformations. **Objective:** In the present study, we compare the efficacy and complications of the long-pulse pulsed dye laser (LPPDL) and the long-pulse pulsed alexandrite laser (LPPAL) in the treatment of PWSs. **Methods:** Eleven patients with Fitzpatrick skin types III–IV were enrolled in this study. One section of each patient's PWS was treated with LPPDL and another section was treated with LPPAL. The patients' PWSs were evaluated for efficacy of elimination of erythema and for treatment-related side effects. **Results:** Both LPPDL and LPPAL treatment are effective in the treatment of PWSs. Hyperpigmentation was seen in two areas treated with LPPDL and in three areas treated with LPPAL. Hypopigmentation was seen in one area treated with LPPAL, but not in any of the areas treated with LPPDL. There was no scarring. **Conclusion:** LPPAL works best with hypertrophic, purple PWSs, while LPPDL yields better clinical improvements with the flat, pink PWSs. Targeting of deoxyhemoglobin, deeper penetration, and higher fluence may explain the effectiveness of LPPAL in purple, hypertrophic PWSs. However, there is a risk of dyspigmentation when using the LPPAL.

Key words: Long-pulse pulsed alexandrite laser, long-pulse pulsed dye laser, port wine stains

Introduction

Port wine stains (PWSs) are commonly treated by the pulsed dye laser (PDL) as standard therapy (1). However, in the majority of cases, complete clearance cannot be achieved and a significant proportion of lesions are resistant to this treatment. In recent studies, the long-pulse pulsed alexandrite laser was used to treat different vascular lesions (2–5). In the millisecond mode, this laser has been widely used for hair removal and for leg vein treatments. It may have an important role in the treatment of bulky malformations and mature PWSs. These lesions are typically more resistant to the PDL due to the predominance of larger and deeper vessels and a higher content of deoxygenated hemoglobin (6,7). Longer wavelengths penetrate deeper, allowing targeting of deeper vessels. However, higher fluences are needed, which in turn increases the potential for epidermal heating due to competitive absorption by epidermal melanin. This is especially important in

darker skin patients because of the increased risk of side effects, such as dyspigmentation and scarring. The aim of our study is to evaluate the clinical efficacy and complication rate when utilizing these two lasers in the treatment of Asian patients with PWSs.

Materials and methods

Eleven patients with Fitzpatrick skin types III–IV were recruited in this study. The participants ranged from 1 to 47 years of age; three patients were male and eight patients were female. Signed written consent forms were obtained from patients or their guardians before participants entered the trial.

Laser treatment

A single operator (TK) treated all the participants. Each patient had one section of his or her PWS treated with the long-pulse pulsed dye laser

(LPPDL) and another section of the PWS treated with the long-pulse pulsed alexandrite laser (LPPAL). A LPPDL (model V-beam; Candela Corporation, Wayland, MA, USA) with a wavelength of 595 nm and a LPPAL (model GentleLase; Candela Corporation) with a wavelength of 755 nm were used. In order to compare these two lasers, we used a spot size of 7 mm and a pulse duration of 3 ms with the LPPDL, and a spot size of 8 mm and a pulse duration 3 ms with the LPPAL. The fluence that resulted in a desirable clinical end point with each laser was used. In the LPPDL site, an end point of uniform purple without whitening was selected, with a fluence between 13 and 15 J/cm². In the LPPAL site, the fluence was between 35 and 50 J/cm², with the end point being an ash grey appearance. Postoperatively, antibiotic ointment was applied to the treatment area. Participants were advised to avoid sun exposure, scrubbing or abrasion of the lesion after laser treatment.

Assessment of response

Patients were monitored postoperatively at 1, 4 and 12 weeks after laser treatment. A research assistant took clinical photographs in a standard manner before laser treatment and at each follow-up appointment. The degree of elimination of erythema due to laser treatment was assessed with erythema reflectance spectrometry (Dermaspectrometer; Cortex Technology, Hagland, Denmark). Two independent, blinded observers reviewed the clinical photographs and assessed the degree of complications, such as scarring, hypopigmentation, and hyperpigmentation. The examination took place with the aid of an operating theater light, with scarring defined as hypertrophic, raised, or atrophic. Pigmentary changes were defined as hyper- or

hypopigmented when compared with the adjacent area of normal skin.

Results

The mean number for the erythema index was 22.4 ± 11.2 in the LPPDL site and 20.6 ± 7.53 in the LPPAL site, compared with 26.5 ± 9.9 in the pretreatment lesions (Figure 1). The lesions achieved more lightening with LPPAL than with LPPDL, but the difference was not significant (Figure 2). LPPAL works best with hypertrophic, purple PWSs; while LPPDL yields better clinical improvements with the flat, pink PWSs (Figures 3 and 4). Hyperpigmentation was seen in two out of the 11 areas treated with LPPDL and in three areas treated with LPPAL. Hypopigmentation was seen in one out of the 11 areas treated with LPPAL, but not in any of the areas treated with LPPDL (Table 1). There was no scarring.

Discussion

PWSs are congenital, hypervascular malformations which produce a dark pink appearance on the surface of the skin and which may evolve into nodular, purple lesions in adulthood. For nearly two decades, the PDL has been the treatment of choice for PWSs (8–15). Although almost all PWSs lighten after a series of PDL treatments, most PWSs cannot be removed completely, even after six to 10 treatments, and further treatment often yields no improvement. Dark, mature PWS lesions can extend 3–5 mm deep (11,16), while the PDL, with a wavelength of 585–600 nm, extends to only 1–2 mm deep. The PDL does not penetrate deep enough to target deep dermal vessels (17). Also, it is




Figure 1. The improvement of erythema after laser therapy.




Figure 2. Comparison of erythema improvement after treatment with each laser.

recognized that the ectatic capillaries in PWSs range in diameter from 10 to > 100 μm (18). These vessels may be too large in diameter or may carry blood too quickly; therefore, sufficient energy cannot be generated to damage the vessels irreversibly (10). These large, partially coagulated vessels are probably not destroyed and subsequently regenerate. Likewise, no coagulation of deeper vessels was noted in PWSs with multiple vascular layers because almost all of the laser light is absorbed in the more superficial vessels. Furthermore, Kane et al. (11) also suggested that the formation of a fibrous shield in the upper papillary dermis (generated by destruction of superficial vessels from previous PDL treatments) might progressively obstruct laser light from penetrating into the deeper dermal vessels.

To counter these difficulties, near infrared wavelength 755-nm LPPAL have been explored for the

treatment of PWSs (6). No et al. used a 3-ms alexandrite laser with dynamic cooling to treat three patients with hypertrophic PWSs, using fluences ranging from 30 to 85 J/cm^2 . All lesions significantly lightened, without side effects.

The effectiveness of LPPAL treatment may be caused by several phenomena. The longer wavelength of the LPPAL (755 nm) results in greater absorption of deoxyhemoglobin when compared with oxyhemoglobin (19). Therefore, targeting of deoxyhemoglobin, which is prevalent in hypertrophic, purple PWS lesions, with the LPPAL results in higher clearance rates when compared with the LPPDL.

Deeper penetration by the longer wavelength of the LPPAL is another reason for its effectiveness. With the longer wavelength of 755 nm, there is greater depth of penetration of the laser energy, and




Figure 3. Left-hand side is before treatment and right-hand side is three months after treatment: case 1.




Figure 4. Left-hand side is before treatment and right-hand side is three months after treatment: case 2.

Table 1. Complications ($n=11$).

	Hyperpigmentation	Hypopigmentation	Scar formation
LPPDL	2/11	0/11	0/11
LPPAL	3/11	1/11	0/11

larger and deeper vasculature can be targeted. Longer wavelengths are also able to penetrate ectatic capillary walls more effectively and thus are more effective at heating the center of the vessels.

In addition, the higher fluences used with the LPPAL contribute to its effectiveness. When similar spot sizes, pulse durations, and DCD (Dynamic cooling device) parameters were used with these two lasers, the fluence that resulted in the clinical end point that we were looking for in the treatment of the PWSs was quite different. In our study, the maximum fluence was 15 J/cm² in the LPPDL treatment sites, compared with 50 J/cm² in the LPPAL treatment sites. Therefore, when we used the LPPAL (with much higher fluences) in the treatment of purple, hypertrophic PWSs, the resultant bulk dermal heating may be more effective.

However, higher fluences increase the potential for epidermal heating due to competitive absorption by epidermal melanin, especially in dark-skinned patients. In our study, there was the possibility of dyspigmentation in the patients with darker skin treated with the LPPAL.

Conclusion

In this study, we found that both the LPPAL and the LPPDL are effective for the treatment of PWSs. The LPPAL acts well with the hypertrophic, purple PWSs, while the LPPDL yields more improvement with the flat, pink PWSs. Clinically, when treating patients with darker skin types, caution is warranted because there is a possible risk of dyspigmentation after laser therapy. Further studies with larger patient numbers are necessary to optimize this treatment.

References

1. Tan OT, Morrison P, Kurban AK. 585nm for the treatment of port wine stains. *Plast Reconstr Surg.* 1990;86:1112-17.
2. Seto Y, Kataoka M, Tsuge K. Stability of blood carbon monoxide and hemoglobins during heating. *Forensic Sci Int.* 2001;121:144-50.
3. Brunnberg S, Lorenz S, Landthaler M, Hohenleutner U. Evaluation of the long pulsed high fluence alexandrite laser therapy of leg telangiectasia. *Lasers Surg Med.* 2002;31:359-62.
4. Kauvar ANB, Lou WWW. Pulsed alexandrite laser for the treatment of leg telangiectasia and reticular veins. *Arch Dermatol.* 2000;136:1371-5.
5. McDaniel H, Ash K, Lord J, Newman J, Adrian RM, Zukows Ki M. Laser therapy of spider leg veins: clinical evaluation of a new long pulsed alexandrite laser. *Dermatol Surg.* 1999;25:52-8.
6. No D, Dierickx C, McClaren M. Pulsed alexandrite treatment of bulky vascular malformations. *Lasers Surg Med.* 2003;15(suppl):26 (abstr.).
7. Yang MU, Yaroslavsky AN, Farinelli WA, Flotte TJ, Rius-Diaz F, Tsao SS, et al. Long pulsed Nd:YAG laser treatment for port wine stains. *Lasers Surg Med.* 2003;15(suppl):28 (abstr.).
8. Woo WK, Handley JM. Pulsed dye laser treatment of port-wine stains: clinical response and treatment characteristics. *Br J Dermatol.* 2002;147(suppl 62):60 (abstr.).
9. Katugampola GA, Lanigan SW. Five years experience of treating port wine stains with the flashlamp-pumped pulsed dye laser. *Br J Dermatol.* 1997;137:750-4.
10. Hohenleutner U, Hillbert M, Wlotzke U, Landthaler M. Epidermal damage and limited coagulation depth with the flashlamp-pumped pulsed dye laser: a histochemical study. *J Invest Dermatol.* 1995;104:798-802.
11. Kane KS, Smoller BR, Fitzpatrick RE, Walker NP, Dover JS. Pulsed dye laser-resistant port wine stains. *Arch Dermatol.* 1996;132:839-41.
12. Anderson RR, Parrish JA. The optics of human skin. *J Invest Dermatol.* 1981;77:13-19.
13. Kono T, Sakurai H, Takeuchi M, Yamaki T, Soejima K, Groff WF, et al. Treatment of resistant port-wine stains with a variable-pulse pulsed dye laser. *Dermatol Surg.* 2007;33:1-6.
14. Bernstein EF. Treatment of a resistant port wine stain with the 1.5 msec pulse duration, tunable, pulsed dye laser. *Dermatol Surg.* 2000;26:1007-9.
15. Raulin C, Hellwig S, Schonemark MP. Treatment of a nonresponding port wine stain with a new pulsed light source (Photo-Derm VL). *Lasers Surg Med.* 1997;21:203-8.
16. Tan OT, Murray S, Kurban AK. Action spectrum of vascular specific injury using pulsed irradiation. *J Invest Dermatol.* 1989;92:868-71.
17. Douven LFA, Lucassen GW. Retrieval of optical properties of skin from measurement and modeling the diffuse reflectance. *Proc Soc Photo Opt Instrum Eng.* 2000;3914:312-23.
18. Verkruysse W, Van Gemert MJ, Smithies DJ, Nelson JS. Modelling multiple laser pulses for port wine stain treatment. *Phys Med Biol.* 2000;45:197-203.
19. Kuenstner JT, Norris KH. Spectrophotometry of human hemoglobin in the near infrared region from 1000 to 2500 nm. *J Near Infrared Spectrosc.* 1994;2:59-65.